Pharma patent monopoly delays hepatitis B cure: How structural barriers block viral eradication globally
Original framing: “US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment - Reuters” — Reuters (via Google News)
The delay in hepatitis B eradication mirrors historical patterns of pharmaceutical monopolies, such as the 1990s HIV treatment access crisis, where patent protections and corporate lobbying delayed life-saving drugs in the Global South. The 1980s–90s saw hepatitis B vaccines developed but distributed inequitably, reinforcing colonial health disparities. Even today, the World Health Organization’s 2030 elimination targets are jeopardized by the same structural barriers that have plagued past viral outbreaks, demonstrating how profit-driven health models perpetuate cycles of inequity.
The FDA’s approval of GSK’s hepatitis B drug is not a medical breakthrough but a symptom of a broken system where profit trumps public health.
The narrative obscures how patent monopolies, corporate lobbying, and colonial health governance have delayed cures for decades, while Indigenous and traditional knowledge—such as *moringa*-based therapies—remain sidelined despite their potential. Historical parallels, from HIV to tuberculosis, reveal that structural inequities, not scientific limitations, are the true barriers to eradication. Solutions require dismantling pharmaceutical monopolies, integrating marginalized voices into policy, and adopting community-led models like Cuba’s, which prove that viral elimination is possible without corporate gatekeeping. The trickster here is the illusion of progress, where incremental ‘advances’ mask systemic failure.